利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.018 秒)

    Alzheimer's related proteins and methods of use
    1.
    发明授权
    Alzheimer's related proteins and methods of use 有权

    公开(公告)号：US06383758B1

    公开(公告)日：2002-05-07

    申请号：US09227725

    申请日：1999-01-08

    申请人： Peter H. St. George-Hyslop ,  Paul E. Fraser

    发明人： Peter H. St. George-Hyslop ,  Paul E. Fraser

    IPC分类号： G01M3353

    CPC分类号： C07K14/4711 ,  G01N33/5091 ,  G01N33/566 ,  G01N33/6875 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2500/00 ,  G01N2800/2821

    摘要： Disclosed is a method for identifying substances that alter the interaction of a presenilin protein with a presenilin-binding protein, including contacting at least the interacting domain of a presenilin protein to a presenilin-binding protein in the presence of a test substance, and measuring the interaction of the presenilin protein and the presenilin-binding protein. Also disclosed is method for identifying substances that modulate the nuclear translocation of an armadillo protein, including providing a culture of cells that express the armadillo protein and a mutant presenilin protein, or a functional fragment thereof that binds an armadillo protein; contacting the culture with a test substance; inducing nuclear translocation of the armadillo protein in the cells; and measuring levels of nuclear armadillo protein as compared to a control as an indication of modulatory activity of the test substance. Further disclosed is method for screening individuals for presenilin alleles associated with Alzheimer's Disease or related disorders, including obtaining cells from an individual to be tested for Alzheimer's Disease or a related disorder; inducing nuclear translocation of an armadillo protein in the cells; and measuring levels of the nuclear armadillo protein as compared to a control as an indication of the presence or absence of presenilin alleles associated with Alzheimer's Disease or a related disorder.

    Immunoassay for quantitative determination of the complex between prostate specific antigen (PSA) and &agr;2-macroglobulin (A2M) in a sample
    2.
    发明授权
    Immunoassay for quantitative determination of the complex between prostate specific antigen (PSA) and &agr;2-macroglobulin (A2M) in a sample 失效
    用于定量测定样品中前列腺特异性抗原（PSA）和α2-巨球蛋白（A2M）之间的复合物的免疫测定

    公开(公告)号：US06632623B1

    公开(公告)日：2003-10-14

    申请号：US09700586

    申请日：2001-01-10

    申请人： Ulf-Håkan Stenman

    发明人： Ulf-Håkan Stenman

    IPC分类号： G01M3353

    CPC分类号： G01N33/57434

    摘要： This invention concerns an immunoassay for quantitative determination of the amount of the complex (PSA-A2M) between prostate specific antigen (PSA) and &agr;2-macroglobulin (A2M) in a sample. The assay comprises the steps of removing immunoreactive PSA from the sample, treating the PSA-A2M complex in the remaining supernatant so as to make the PSA thereof immunoreactive, determining the immunoreactive PSA derived from the PSA-A2M complex by exposing it to an antibody which binds immunoreactive PSA, and detecting the PSA. The invention also concerns a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) or healthy male subjects without PCa, wherein the individual's body fluid concentration of PSA has been determined as free PSA and as total PSA. The method is characterized in that PSA complexed with A2M (PSA-A2M) in the individual's serum sample has been determined, and that the ration between PSA-A2M and other forms of PSA is calculated, or that the diagnostic value is calculated by logistic regression, neural networks, fussy logic or similar mathematical and statistical methods using PSA-A2M and other forms of PSA, such as total PSA, free PSA and PSA-ACT as input variables.

    摘要翻译： 本发明涉及用于定量测定前列腺特异性抗原（PSA）和α PDAT> 2之间的复合物（PSA-A PDAT> 2）的量的免疫测定 - 巨球蛋白（A 2 M）。 该测定包括从样品中除去免疫反应性PSA的步骤，在剩余的上清液中处理PSA-A PDTA> 2复合物，以使其PSA具有免疫反应性，确定免疫反应性 将其通过将其暴露于结合免疫反应性PSA的抗体和检测PSA而从PSA-A PDAT> 2 本发明还涉及用于将患有前列腺癌（PCa）的患者与患有良性前列腺增生症（BPH）的患者或没有PCa的健康男性受试者区分开的方法，其中个体的PSA体液浓度已被确定为游离PSA和总计 PSA。 该方法的特征在于在个体的血清样品中与A 2 M（PSA-A 2 已经确定，并且计算PSA-A 2 M和其他形式的PSA之间的比例，或者诊断值通过逻辑回归，神经网络，fussy 逻辑或类似的数学和统计方法，使用PSA-A 2 M和其他形式的PSA，如总PSA，游离PSA和PSA-ACT作为输入变量。 >

    Diagnosis of early gastric cancer
    6.
    发明授权
    Diagnosis of early gastric cancer 有权
    早期胃癌的诊断

    公开(公告)号：US06416961B1

    公开(公告)日：2002-07-09

    申请号：US09381042

    申请日：1999-09-14

    申请人： Ari Ristimäki ,  Matti Härkönen ,  Pentti Sipponen

    发明人： Ari Ristimäki ,  Matti Härkönen ,  Pentti Sipponen

    IPC分类号： G01M3353

    CPC分类号： C12Q1/6841 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57446 ,  G01N33/57484

    摘要： The present invention pertains to a method for determination of the significance of a histologically detected premalignant lesion as a risk for intestinal type gastric cancer or carcinoma in situ, comprising detecting from a patient sample comprising gastric mucosa cells a) cyclooxygenase-2 Cox-2) mRNA expression, or b) Cox-2 protein; wherein overexpression of Cox-2 is indicative of an increased risk for intestinal type gastric cancer.

    摘要翻译： 本发明涉及一种用于确定组织学检测的恶化前病变作为肠型胃癌或原位癌的风险的意义的方法，包括从包含胃粘膜细胞的患者样品检测a）环加氧酶-2 Cox-2）mRNA 表达，orb）Cox-2蛋白;其中Cox-2的过表达指示肠型胃癌的风险增加。